On December 9-10, 2022, Professor Chen Li, Vice President of the Shenzhen Institute of Advanced Technology and Director of the Key Laboratory of Quantitative Engineering Biology at the Chinese Academy of Sciences, led a delegation to visit the Swiss Federal Institute of Technology (EPFL), where the core technology of Leman Biotech was developed.
During the visit, Professor Liu and his team visited the Laboratory of Biomaterials for Immunoengineering, lead by Professor Li Tang, co-founder of Leman Biotech, and the Swiss R&D center of Leman Biotech located at the Biopôle in Lausanne. Professor Liu, Director Cai Lintao, Director Wang Liping, and Professor Tang held in-depth discussions on cancer immunotherapy and the clinical translation of scientific research, and reached agreements on areas of mutual interest.
Leman Biotech is a clinical-staged cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and AI-driven drug R&D leader XtalPi. The company combines innovative metabolic reprogramming technology with cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. The core technology Meta 10 has the potential to cure solid tumors, as demonstrated in the published research in the top academic journal Nature Immunology, and has PCT patents in 56 countries and regions, covering major economies in the world. The company has a highly qualified R&D team, with over 70% of its personnel having graduated from esteemed Chinese and international universities and holding extensive industrial experience. Several of Leman Biotech's R&D pipelines are in advanced stage of development, including a metabolically armed CAR-T cell therapy in IIT clinical research stage. In December 2021, just half a year after its inception, Leman Biotech completed a successful angel round of financing, raising nearly $11 million, with plans for further financing underway. Leman Biotech is committed to finding solutions to the bottlenecks in cancer immunotherapy, improving the response rate and efficacy, and making unremitting efforts to achieve the ultimate goal of curing cancer.
